Mostrar o rexistro simple do ítem

dc.contributor.authorSeoane, Samuel
dc.contributor.authorBermúdez, María José
dc.contributor.authorSendón Lago, Juan José
dc.contributor.authorMartínez Ordóñez, Anxo
dc.contributor.authorAbdul-Hadi, Soraya
dc.contributor.authorMaestro, Miguel
dc.contributor.authorMouriño, Antonio
dc.contributor.authorPérez-Fernández, Román
dc.date2013
dc.date.accessioned2017-09-26T08:09:08Z
dc.date.available2017-09-26T08:09:08Z
dc.identifier.citationCancers 2014, Vol. 6, Pages 67-78es_ES
dc.identifier.issn2072-6694
dc.identifier.urihttp://hdl.handle.net/2183/19529
dc.description.abstractIt has been demonstrated that 1,25-dihydroxyvitamin D3 (1,25D) and some of its analogues have antitumor activity. 1,25D labeled with deuterium (26,26,26,27,27,27-hexadeuterated 1a,25-dihydroxyvitamin D3, or 1,25D-d6) is commonly used as internal standard for 1,25D liquid chromatography-mass spectrometry (LC-MS) quantification. In the present study using human breast cancer cell lines, the biological activity of 1,25D-d6 administered alone and in combination with two commonly used antineoplastic agents, 5-fluorouracil and etoposide, was evaluated. Using an MTT assay, flow cytometry, and western blots, our data demonstrated that 1,25D-d6 has effects similar to the natural hormone on cell proliferation, cell cycle, and apoptosis. Furthermore, the combination of 1,25D-d6 and etoposide enhances the antitumoral effects of both compounds. Interestingly, the antitumoral effect is higher in the more aggressive MDA-MB-231 breast cancer cell line. Our data indicate that 1,25D-d6 administered alone or in combination with chemotherapy could be a good experimental method for accurately quantifying active 1,25D levels in cultures or in biological fluids, on both in vitro breast cancer cell lines and in vivo animal experimental models.es_ES
dc.description.sponsorshipMinisterio de Economía y Competividad; SAF2012-38240es_ES
dc.description.sponsorshipMinisterio de Educación e Innovación. MEI; SAF2010-15291es_ES
dc.description.sponsorshipXunta de Galicia; CN2012/074es_ES
dc.description.sponsorshipXunta de Galicia; INCITE08PXIB209130PRes_ES
dc.language.isoenges_ES
dc.publisherMultidisciplinary Digital Publishing Institutees_ES
dc.relation.urihttp://dx.doi.org/10.3390/cancers6010067es_ES
dc.rightsReconocimiento 3.0es_ES
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/
dc.subject1a,25-dihydroxyvitamin d<sub>3</sub>es_ES
dc.subject26,26,26,27,27,27-hexadeuterated 1a,25-dihydroxyvitamin d<sub>3</sub>es_ES
dc.subjectVitamin des_ES
dc.subjectDeuterated vitamin des_ES
dc.subjectChemotheraphyes_ES
dc.subjectBreast canceres_ES
dc.title26,26,26,27,27,27-Hexadeuterated-1,25-Dihydroxyvitamin D3 (1,25D-d6) As Adjuvant of Chemotherapy in Breast Cancer Cell Lineses_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.accessinfo:eu-repo/semantics/openAccesses_ES
UDC.journalTitleCancerses_ES
UDC.volume6es_ES
UDC.issue1es_ES
UDC.startPage67es_ES
UDC.endPage78es_ES


Ficheiros no ítem

Thumbnail
Thumbnail

Este ítem aparece na(s) seguinte(s) colección(s)

Mostrar o rexistro simple do ítem